How a Failed Endpoint May Fast-Track the First Oral Snakebite Antidote

CORTE MADERA, Calif. – September 22, 2026 – In the high-stakes world of clinical biotech, a missed primary endpoint is usually the death knell for an investigational drug. But in the notoriously complex field of neglected tropical diseases, conventional trial metrics often clash with biological reality. Such is the case for Ophirex, Inc., a Public Benefit Corporation that recently published the results of its Phase 2 BRAVIO trial in PLOS Neglected Tropical Diseases.

The trial, which evaluated the company’s lead candidate, varespladib, as a treatment for snakebite envenomation, technically failed to meet its primary efficacy endpoints. Yet, a deeper look at the data—and the company's subsequent strategic pivot—reveals a masterclass in regulatory navigation and a stark reminder of why the U.S. Department of Defense is heavily invested in venom research.

By leveraging compelling subgroup data and securing an agreement to pursue the FDA's rare Animal Rule pathway, Ophirex is bypassing the logistical impossibilities of human field trials. In doing so, it is keeping the dream of a field-ready, oral snakebite antidote alive.

The Paradox of Late-Stage Intervention

Snakebite envenomation is a profound global health crisis, killing between 80,000 and 138,000 people annually and leaving another 400,000 with permanent disabilities. The vast majority of these deaths occur in rural, resource-limited areas—particularly in India, which accounts for over 50,000 fatalities each year.

Currently, the only available treatment is antivenom, a species-specific, cold-chain-dependent biologic that must be administered intravenously in a hospital setting. The core problem is time: venom destroys tissue and paralyzes respiratory systems long before patients can reach an intensive care unit.

Varespladib was designed to bridge this gap. It is a small-molecule inhibitor targeting secretory phospholipase A2 (sPLA2), a highly toxic enzyme present in the venom of more than 95% of venomous snakes. The Phase 2 BRAVIO trial enrolled 140 hospitalized patients across 18 sites in the United States and India, testing intravenous followed by oral varespladib as an adjunct to standard antivenom.

The trial missed its prespecified primary endpoints: accelerating the time to recovery of a 5-second head-lift in elapid envenoming, and reducing the area under the curve of a Snakebite Severity Score in viper envenoming. However, the failure was largely a function of trial design rather than drug efficacy. On average, varespladib was initiated 7.3 hours after the snakebite and 3.3 hours after antivenom administration. By that time, irreversible presynaptic nerve damage and systemic hemorrhage had already occurred.

"The study drug was initiated an average of seven hours after snakebite and following the administration of antivenom, making it difficult to measure the true effect of sPLA2 inhibition," said Charles J. Gerardo, MD, co-lead author and Professor at Duke University Hospital. "Giving antivenom up front was necessary due to the severity of snakebite envenomation within the trial. Nonetheless, varespladib, as a late adjunctive therapy, was associated with clinically meaningful signals of benefit in krait and copperhead patients. These results are consistent with the known mechanism of action of varespladib and point to the need for further studies."

In patients bitten by kraits—a highly venomous elapid native to the Indian subcontinent—those treated with varespladib spent approximately half as much time on mechanical ventilation (21 hours versus 40 hours) and experienced a 36% lower illness severity over the first week. For a rural Indian hospital with limited ventilator capacity, halving intubation time is a massive clinical and economic win. Similarly, patients bitten by copperheads in the U.S. saw a 43% reduction in illness severity over the first two weeks.

Pivoting to the FDA Animal Rule

The BRAVIO results confirmed a critical biological reality: sPLA2 inhibition works, but it must be administered immediately after the bite to prevent irreversible damage. This presents an insurmountable regulatory hurdle. Conducting a double-blind, placebo-controlled trial where rural farmers are given an experimental pill within 15 minutes of a bite—without immediate antivenom—is ethically impermissible and logistically impossible.

Recognizing this, Ophirex has secured alignment to pursue marketing approval under the FDA’s Animal Rule (21 CFR Part 314, Subpart I). Historically reserved for chemical, biological, radiological, and nuclear (CBRN) threats like anthrax and smallpox, this regulatory framework allows for approval based on human safety data and rigorous efficacy studies in validated animal models.

"The results in krait- and copperhead-bite patients are aligned with the benefits observed in animal experiments," said Timothy Platts-Mills, M.D., MSc, Chief Medical Officer of Ophirex. "To study the effects of varespladib in humans in a use case more similar to its intended use – as an oral rescue treatment administered at the time of bite, before antivenom – Ophirex is continuing the study of varespladib via the FDA’s Animal Rule... If approved, we anticipate additional post-approval clinical studies will evaluate the effects of prehospital and early in-hospital treatment."

This pivot fundamentally de-risks the company's clinical pipeline. With safety already established across approximately 4,600 historical trial subjects from the drug's previous iterations in cardiovascular research, Ophirex's burden now shifts entirely to demonstrating survival in large animal models and establishing a pharmacokinetic bridge to human dosing.

"There is a significant unmet need for a snakebite treatment that can be administered at the time of bite to immediately inhibit the effects of snake venom," noted Jeremy Gowler, CEO of Ophirex. "We are committed to continuing varespladib’s development, and efficacy studies in animals are underway."

The Pentagon's Strategic Interest in Venom

The push for an oral snakebite antidote is not just a global health initiative; it is a matter of military logistics and force protection. Ophirex’s development is heavily backed by the U.S. Department of Defense, specifically through the Defense Health Agency’s Small Business Innovation Research (DHA SBIR) program and the Warfighter Protection and Acute Care (WPAC) team.

The military's operational rationale is clear. U.S. Indo-Pacific Command (INDOPACOM) forces frequently operate in dense, austere jungle environments teeming with kraits, cobras, and pit vipers. Traditional antivenom is useless in a tactical combat backpack; it requires continuous refrigeration, intravenous reconstitution, and a critical care team to manage the high risk of anaphylactic shock.

A shelf-stable, oral pill that can be administered immediately by a combat medic fundamentally changes the geometry of tactical evacuation. By pausing the systemic spread of venom, varespladib could keep a soldier breathing long enough to survive a delayed medical evacuation. For the Pentagon, funding a neglected tropical disease drug is a direct investment in battlefield survivability, a sentiment echoed by independent defense logistics analysts familiar with the military's acute care portfolio.

A Veterinary Beachhead and the Path Forward

As Ophirex navigates the complex bridging studies required for a projected 2027 New Drug Application, the company is also executing a shrewd commercial strategy to generate near-term runway. In 2025, varespladib received Minor Use in Major Species (MUMS) designation from the FDA’s Center for Veterinary Medicine for the treatment of snakebite in dogs.

With tens of thousands of canine snakebites occurring annually in the United States—and veterinary antivenom costing thousands of dollars per vial—the companion animal market offers a highly lucrative, immediate commercial beachhead. This dual-track strategy ensures that the Public Benefit Corporation can remain solvent while advancing its human clinical goals.

Furthermore, the competitive landscape of venom therapeutics is evolving. While next-generation recombinant monoclonal antibodies are in development at various academic centers, they remain injectable biologics. The ultimate holy grail of snakebite treatment will likely be a combination of small molecules—pairing an sPLA2 inhibitor like varespladib with a metalloproteinase inhibitor to neutralize both neurotoxic paralysis and hemorrhagic tissue necrosis.

By embracing the realities of envenomation biology and leveraging an unconventional regulatory pathway, Ophirex has transformed a clinical trial failure into a viable roadmap. The BRAVIO data may not have hit its primary p-values, but it proved that intercepting venom at the source is possible. If the Animal Rule strategy succeeds, a simple oral pill could soon disarm one of the world's most neglected and deadly environmental hazards.